A revolutionary gene-editing therapy has successfully cleared “incurable” leukemia in children during a world-first clinical trial. Developed by scientists at Great Ormond Street Hospital and University College London, the treatment uses base-edited T-cells from healthy donors to hunt down and destroy cancer cells. This “off-the-shelf” therapy has already achieved remission in patients who had exhausted all other options.
A breakthrough gene therapy is offering unprecedented hope for families battling Huntington’s disease (HD), a fatal neurodegenerative disorder. Trial results show the one-time therapy successfully slowed disease progression by 75% in patients. This major victory, developed by scientists at University College London, is the first treatment to truly modify the disease’s course. It transforms a devastating, inherited diagnosis into a manageable condition, accelerating research for other neurological disorders like Alzheimer’s.
A new form of prostate cancer surgery nearly doubles the chances of men retaining erectile function, according to a new trial conducted by University College London. Known as NeuroSafe, the procedure checks tissue removed during the operation. If the tumor appears to have been removed, the nerve-containing outer layer of the prostate is left intact. The trial assessed 344 men with prostate cancer and no history of erectile dysfunction. 56% of men who had standard surgery reported severe erectile dysfunction, compared with 38% who had NeuroSafe surgery.
Doctors are hailing a “remarkable” new treatment regime for cervical cancer developed by researchers at University College London that reduces the risk of dying by 40%, in the biggest advance against the disease in 25 years. The new treatment plan was tested in patients recruited over 10 years from the UK, Mexico, India, Italy, and Brazil. Cervical cancer is the fourth most common cancer in women globally, with about 660,000 new cases and 350,000 deaths every year, according to the World Health Organization.
